scispace - formally typeset
J

Julia A. Schweiger

Researcher at Washington University in St. Louis

Publications -  9
Citations -  128

Julia A. Schweiger is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Weight loss & Randomized controlled trial. The author has an hindex of 5, co-authored 9 publications receiving 81 citations.

Papers
More filters
Journal ArticleDOI

Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.

TL;DR: Adverse changes in adiposity and insulin sensitivity were observed during 12 weeks of antipsychotic treatment in youths, with the greatest fat increases on olanzapine, may be associated with risk for premature cardiometabolic morbidity and mortality.
Journal ArticleDOI

Getting to More Effective Weight Management in Antipsychotic-Treated Youth: A Survey of Barriers and Preferences.

TL;DR: The results suggest that targets for obesity treatment in this population include individualized, specific support that takes into account the child's motivation, which is effected by psychiatric symptoms.
Journal ArticleDOI

A Smartphone-Based Technique to Detect Dynamic User Preferences for Tailoring Behavioral Interventions: Observational Utility Study of Ecological Daily Needs Assessment.

TL;DR: The results of this utility study suggest the importance of personalization and learning algorithms for sustaining app engagement in young adults with psychiatric conditions, and provides an individually dynamic and contextually relevant alternative and complement to traditional needs assessment for assessing individually dynamic user needs and preferences during treatment development or adaptation.
Journal ArticleDOI

Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial.

TL;DR: Three bupropion XL 300 mg generic products are both bioequivalent and not therapeutically different from brand drug and each other, and three generics met formal bioequivalence criteria for buPropion and metabolites.